WO2025108148 - CAS PROTEIN HAVING IMPROVED ACTIVITY AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2025/108148
Publication Date
30.05.2025
International Application No.
PCT/CN2024/131715
International Filing Date
13.11.2024
Title **
[English]
CAS PROTEIN HAVING IMPROVED ACTIVITY AND USE THEREOF
[French]
PROTÉINE CAS PRÉSENTANT UNE ACTIVITÉ AMÉLIORÉE ET SON UTILISATION
[Chinese]
一种活性改善的CAS蛋白及其应用
Applicants **
SHANDONG SHUNFENG BIOTECHNOLOGY CO.LTD.
Inventors
DUAN, Zhiqiang
CHEN, Ying
Priority Data
202311581901.X
24.11.2023
CN
202311600750.8
28.11.2023
CN
202410831494.1
26.06.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1708 | |
| EPO | Filing, Examination, Granting | 11726 | |
| Japan | Filing, Examination, Granting | 2018 | |
| South Korea | Filing, Examination, Granting | 1853 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
22,045
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention belongs to the field of nucleic acid editing, and particularly the technical field of clustered regularly interspaced short palindromic repeats (CRISPRs). Specifically, provided in the present invention is a Cas mutant protein having an improved activity and an improved editing efficiency. Compared with a wild-type parental Cas protein, the Cas mutant protein of the present invention has significantly improved activity, and has a wide application prospect.[French]
La présente invention appartient au domaine de l'édition des acides nucléiques, et plus particulièrement au domaine technique des courtes répétitions palindromiques groupées régulièrement espacées (CRISPR). Plus spécifiquement, la présente invention fournit une protéine mutante Cas présentant une activité améliorée et une efficacité d'édition améliorée. Comparée à une protéine Cas parentale de type sauvage, la protéine Cas mutante de la présente invention présente une activité nettement améliorée, et ses perspectives d'application sont vastes.[Chinese]
本发明属于核酸编辑领域，特别是规律成簇的间隔短回文重复(CRISPR)技术领域。具体而言，本发明提供了一种活性改善、编辑效率提高的Cas突变蛋白，相对于野生型亲本Cas蛋白，本发明的Cas突变蛋白活性显著提高，具有广泛的应用前景。